Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Cash from Financing Activities: 2012-2025

Historic Cash from Financing Activities for Agios Pharmaceuticals (AGIO) over the last 13 years, with Sep 2025 value amounting to $4.4 million.

  • Agios Pharmaceuticals' Cash from Financing Activities rose 68.18% to $4.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.0 million, marking a year-over-year increase of 4.92%. This contributed to the annual value of $14.4 million for FY2024, which is 165.82% up from last year.
  • Latest data reveals that Agios Pharmaceuticals reported Cash from Financing Activities of $4.4 million as of Q3 2025, which was up 6,723.08% from $65,000 recorded in Q2 2025.
  • Agios Pharmaceuticals' 5-year Cash from Financing Activities high stood at $7.3 million for Q1 2021, and its period low was -$503.5 million during Q2 2021.
  • In the last 3 years, Agios Pharmaceuticals' Cash from Financing Activities had a median value of $1.9 million in 2023 and averaged $2.4 million.
  • As far as peak fluctuations go, Agios Pharmaceuticals' Cash from Financing Activities tumbled by 7,379.15% in 2021, and later skyrocketed by 3,750.00% in 2023.
  • Over the past 5 years, Agios Pharmaceuticals' Cash from Financing Activities (Quarterly) stood at -$18.6 million in 2021, then spiked by 100.12% to $22,000 in 2022, then soared by 3,750.00% to $847,000 in 2023, then soared by 471.66% to $4.8 million in 2024, then skyrocketed by 68.18% to $4.4 million in 2025.
  • Its Cash from Financing Activities stands at $4.4 million for Q3 2025, versus $65,000 for Q2 2025 and $1.6 million for Q1 2025.